RETROVIR

250 MG · capsule · box of 40

Historical reference: this presentation is not marketed, withdrawn or suspended according to the source. Its listed price does not establish availability.

Reference dated : 2026-10-01. Confirm price and availability with a pharmacist.

Laboratory

GSK

Composition and presentation

RETROVIR — ZIDOVUDINE. Listed presentation: 250 MG · GELULE · BOITE DE 40.

Full clinical reference

Additional sections are available in French. Read the original document; the information concerns the French reference product.

Uses

Retrovir capsules are indicated as part of antiretroviral combinations for the treatment of adults and children infected with the Human Immunodeficiency Virus (HIV).

Chemoprophylaxis with Retrovir is indicated in pregnant women who are HIV-positive (after 14 weeks of amenorrhea) for the prevention of mother-to-child transmission of HIV and for primary prophylaxis of HIV infection in the newborn.

Driving

No study has evaluated the effect of Retrovir on driving performance or the ability to use machines. Due to the pharmacology of this medicine, no deleterious effect on such activities is expected. However, the clinical state of the patient and the adverse effects of Retrovir should be kept in mind to define the fitness of patients to drive a vehicle or to use machines.

Read the French reference

Commercial status

Retiré du Marché

Therapeutic class

References and update dates

AMMPS — catalogue marocain officiel · 2026-10-01

Product and price reference

This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.

Price history

Reference price recorded since 2026-10-01: Not available in the verified source

Reference price recorded since 2026-06-01: Not available in the verified source

Other strengths and forms

Routes and instructions may differ.